An Eight Week, Double-Blind, Randomized, Multicenter, Parallel Group, Active-Controlled Study Comparing the Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg to Ramipril 5 mg in Patients With Essential Hypertension.
Phase of Trial: Phase III
Latest Information Update: 23 Apr 2013
At a glance
- Drugs Aliskiren (Primary) ; Ramipril
- Indications Essential hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 01 Jan 2012 Results published in Hypertension Research.
- 19 Jun 2010 Results presented at the 17th World Congress of Cardiology.
- 13 Jun 2009 Results presented at the 19th European Meeting on Hypertension.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History